Valeant Pharmaceuticals International, Inc. 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Jan 9, 2015
Insider Transaction Report
Form 4
Pearson J. Michael
DirectorChief Executive Officer
Transactions
- Award
Restricted Share Units
2015-01-07+450,000→ 450,000 total→ Common Shares, no par value (2,250,000 underlying)
Footnotes (3)
- [F1]Each Restricted Share Unit ("RSU") represents a contingent right to receive between zero and five common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (2).
- [F2]The performance based RSUs are eligible to vest on the achievement of TSR targets ranging from 10% to 50% over a base price of $140.63 (i.e., at 10% each vesting RSU earns one Common Share and at 50% each vesting RSU earns five Common Shares) on each of three measurement dates: 25% would vest on October 7, 2019, 50% on January 7, 2020 and 25% on April 7, 2020, with early vesting possible after the third anniversary of the grant date at higher TSR levels.
- [F3]Represents the maximum number of Common Shares that may be issued under the RSU award. See note (2).